We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Early Markers Detected For Epstein Barr Virus

By LabMedica International staff writers
Posted on 03 Dec 2012
Molecular tests that can identify early protein markers produced by Epstein Barr Virus (EBV) may have value for diagnosing active infection.

The benefits of this diagnostic approach in patients with mononucleosis and in EBV-infected transplant patients have been evaluated by comparing three different immunoassays.

Scientists at University College Dublin (Ireland) investigate the diagnostic value of anti-early antigen (EA) immunoglobulin G (IgG) testing in the stage-specific differential diagnosis of EBV infection in immunocompetent individuals with atypical antibody responses. More...
Furthermore, they assessed whether anti-EA IgG detection in conjunction with EBV DNA viral load quantification had better predictive value than EBV DNA alone in the diagnosis of EBV-associated disease in immunosuppressed adult liver transplant recipients. During the study period, none of the patients developed post-transplantation lymphoproliferative disorders (PTLD).

Eighty-five serum or plasma samples from 69 individuals were selected from the archived database. The detection of EA IgG in patients' samples was carried out using three different specific serological assays. The enzyme-linked immunosorbent assay (ELISA) is a microtiter plate assay, which detects and quantifies specific human IgG against EBV p54 EA. The Liaison chemiluminescent immunoassay (CLIA) is a two-step, immunoluminometric sandwich assay using directly coated magnetic particles for the detection of EBV EA IgG against the p54 EA. The recomBlot EBV IgG qualitative immunoblot assay was used as the gold standard. Amplification and quantification of DNA was performed using the Light Cycler EBV Quantification kit (Roche Diagnostics; Mannheim, Germany).

The results showed that the CLIA (DiaSorin; Saluggi, Italy) and immunoblot (Mikrogen; Neuried, Germany) produced more comparable results. However, there was a significant difference between the results of the ELISA (MP Biomedicals; Eschwege, Germany) and the immunoblot EA IgG assays and the results of the CLIA and ELISA assays. Comparisons with the immunoblot results showed that the CLIA is more sensitive (77%) than the ELISA (50%), but that the CLIA is less specific (42%) than the ELISA (100%).

The authors concluded that the automated CLIA was found to be more accurate than the ELISA when using the immunoblot assay as a “gold standard” assay in the detection of EA IgG. There may be a potential role for EA IgG testing, together with EBV viral load, in the prediction of transplant recipients at risk of EBV-associated disease. However, EA IgG does not play a significant role in the differential diagnosis of EBV infection in immunocompetent individuals. The study was published on November 2, 2012, in the journal BioResearch Open Access.

Related Links:

University College Dublin
Roche Diagnostics
DiaSorin



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.